MENU
+Compare
IPHYF
Stock ticker: OTC
AS OF
Jun 24 closing price
Price
$1.95
Change
+$0.21 (+12.07%)
Capitalization
168.08M

IPHYF Innate Pharma Forecast, Technical & Fundamental Analysis

Innate Pharma SA is a clinical-stage biotechnology company... Show more

IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IPHYF with price predictions
Jun 27, 2025

IPHYF in upward trend: price rose above 50-day moving average on June 12, 2025

IPHYF moved above its 50-day moving average on June 12, 2025 date and that indicates a change from a downward trend to an upward trend. In of 18 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for IPHYF crossed bullishly above the 50-day moving average on June 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPHYF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.422) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). IPHYF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (10.718) is also within normal values, averaging (252.247).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHYF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VNSYX23.180.20
+0.87%
Natixis Vaughan Nelson Select Y
TLGYX63.860.53
+0.84%
Touchstone Large Company Growth Y
RCGTX14.850.09
+0.61%
Virtus Zevenbergen Technology C
BILSX9.960.05
+0.50%
BlackRock U.S. Insights Lon/Shr Eq Ins
VGIIX86.140.37
+0.43%
JPMorgan US Value I

IPHYF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHYF has been loosely correlated with MBIO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHYF jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHYF
1D Price
Change %
IPHYF100%
N/A
MBIO - IPHYF
42%
Loosely correlated
-0.97%
HLVX - IPHYF
38%
Loosely correlated
+1.03%
SLRX - IPHYF
33%
Loosely correlated
-0.01%
RVMD - IPHYF
30%
Poorly correlated
-1.52%
GRI - IPHYF
28%
Poorly correlated
-0.78%
More